Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATRA is 110.12M, and currently, short sellers hold a 10.39% ratio of that floaft. The average trading volume of ATRA on May 02, 2024 was 2.66M shares.
ATRA) stock’s latest price update
Atara Biotherapeutics Inc (NASDAQ: ATRA)’s stock price has decreased by -0.80 compared to its previous closing price of 0.69. However, the company has seen a -4.23% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-28 that Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
ATRA’s Market Performance
Atara Biotherapeutics Inc (ATRA) has experienced a -4.23% fall in stock performance for the past week, with a -5.94% drop in the past month, and a 9.77% rise in the past quarter. The volatility ratio for the week is 8.53%, and the volatility levels for the past 30 days are at 8.44% for ATRA. The simple moving average for the last 20 days is -4.06% for ATRA stock, with a simple moving average of -35.76% for the last 200 days.
Analysts’ Opinion of ATRA
Many brokerage firms have already submitted their reports for ATRA stocks, with Mizuho repeating the rating for ATRA by listing it as a “Neutral.” The predicted price for ATRA in the upcoming period, according to Mizuho is $1 based on the research report published on November 09, 2023 of the previous year 2023.
ATRA Trading at -4.21% from the 50-Day Moving Average
After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.30% of loss for the given period.
Volatility was left at 8.44%, however, over the last 30 days, the volatility rate increased by 8.53%, as shares sank -4.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.55% lower at present.
During the last 5 trading sessions, ATRA fell by -4.23%, which changed the moving average for the period of 200-days by -64.90% in comparison to the 20-day moving average, which settled at $0.7117. In addition, Atara Biotherapeutics Inc saw 33.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATRA starting from Touchon Pascal, who sale 24,844 shares at the price of $0.72 back on Mar 04 ’24. After this action, Touchon Pascal now owns 1,910,652 shares of Atara Biotherapeutics Inc, valued at $17,888 using the latest closing price.
Nguyen AnhCo, the EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics Inc, sale 10,746 shares at $0.72 during a trade that took place back on Mar 04 ’24, which means that Nguyen AnhCo is holding 941,397 shares at $7,737 based on the most recent closing price.
Stock Fundamentals for ATRA
Current profitability levels for the company are sitting at:
- -31.42 for the present operating margin
- -0.04 for the gross margin
The net margin for Atara Biotherapeutics Inc stands at -32.21. The total capital return value is set at -11.57. Equity return is now at value -2014.86, with -101.91 for asset returns.
Based on Atara Biotherapeutics Inc (ATRA), the company’s capital structure generated -1.4 points at debt to capital in total, while cash flow to debt ratio is standing at -3.33. The debt to equity ratio resting at -0.58. The interest coverage ratio of the stock is -50.96.
Currently, EBITDA for the company is -264.45 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 13.25. The receivables turnover for the company is 0.25for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
In a nutshell, Atara Biotherapeutics Inc (ATRA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
